Apple’s iOS 12 Update Set To Improve 911 Emergency Calls

Dow 30 component Apple (AAPL) revolutionized personal technology with the introduction of the Macintosh in 1984. Today, Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay and iCloud. Apple’s more than 100,000 employees are dedicated to making the best products on earth, and to “leaving the world better than they found it.”

iOS Help On The Way

With Apple’s new iOS 12 update, set to come out later this year, iPhone users in the U.S. who call 911 will automatically have their location data securely shared with first responders in an effort to reduce emergency response times in an effort to improve the overall outcome.

Nearly 80% of 911 come from mobile devices, and with landline-era infrastructure still in place, accurately locating a mobile caller’s location can be difficult for 911 centers. In 2015, Apple launched HELO (Hybridized Emergency Location) which uses cell towers and on-device data sources such as GPS and WiFi Access Points to estimate a mobile 911 callers location, in order to help improve the challenge. Looking to improve 911 response time, Apple will now also use emergency technology company RapidSOS’s Internet Protocol-based data pipeline along with HELO to improve the 911 centers response time.

What’s “Cookin’?”

Tim Cook, Apple’s CEO stated, “Communities rely on 911 centers in an emergency, and we believe they should have the best available technology at their disposal. When every moment counts, these tools will help first responders reach our customers when they most need assistance.”

With these improvements, Apple is keeping a focus on privacy so that user data will not be used for any non-emergency purpose. The 911 responding center will only have access to the user’s location during the duration of an emergency call.

FCC Likes?

Tom Wheeler, FCC Chairman from 2013 to 2017 stated, “This new functionality is an example of how companies and first responders can use technology to dramatically improve public safety. Lives will be saved thanks to this effort by Apple and RapidSOS.”

Learn more about Apple and track its ongoing progress at Vista Partners Apple (AAPL) Coverage Page.

Free stock photo of fashion, man, person, buildings

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

Apple’s iOS 12 securely and automatically shares emergency location with 911

..

www.apple.com

Read Full Article



Atossa Reports Progress & Results Timeline For Male Breast Enlargement Trial

Seattle based Atossa Genetics Inc. (ATOS) (“Atossa”) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  Atossa is developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement.

Mayo Clinic Research

According to the Mayo Clinic, 25% of men in the U.S. between the ages of 50-69, or approximately 10 million men, suffer from gynecomastia. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen.  For example, in prostate cancer treatment, testosterone is suppressed with androgen deprivation therapy resulting in higher estrogen levels that usually triggers gynecomastia. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International). There is no FDA-approved pharmaceutical to treat gynecomastia. Current therapeutic approaches in these patients include the daily use of oral estrogen-suppressing medications and prophylactic breast bud irradiation which is often repeated.

 

 

 

 

 

Progress Announced!

Today, Atossa announced progress in its Phase 1 study of its proprietary topical Endoxifen in men as it has reported that it has completed dosing and clinical visits. The objectives of the placebo-controlled, repeat dose study of 24 healthy male volunteers are to assess the pharmacokinetics of a proprietary topical Endoxifen dosage form over 28 days, as well as to assess safety and tolerability.

Steve Quay, Ph.D., M.D., President and CEO of Atossa stated, “We are now proceeding to the final stages of this study, which are to complete analysis of blood samples and then collect and analyze the data. We expect to report preliminary results from the study in the next quarter.”

Atossa Reaches Further

In addition to gynecomastia, Atossa is also developing its proprietary topical Endoxifen to reduce Mammographic Breast Density (MBD), which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 34 U.S. states have enacted laws requiring that findings of MBD be communicated to the patient. And according to the National Cancer Institute, approximately 10 million women in the U.S. have high breast density (BI-RADS level C or D with “D” being the highest). Although oral tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral tamoxifen to prevent breast cancer because of the risks of, or actual side-effects of, oral tamoxifen. There is no FDA-approved treatment for MBD.

Atossa is planning a Phase 2 study of its topical Endoxifen in women with MBD. The study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

The primary endpoint of this study is to determine if topical Endoxifen administration results in an individual change in MBD, which will be measured after three and six months. Secondary endpoints are safety and tolerability. The objective of the study is to determine the effect size on MBD between the placebo and active groups, which will permit sample size calculations in a future Phase III study. Enrollment is anticipated to be completed by the end of 2018.

Shares Surge

Shares of Atossa (ATOS) surged to as high as $3/share and traded ~2.62 million shares today and closed at $2.63/share up +5.2%.

Analyst Update

Maxim Group’s Biotechnology Analyst Jason McCarthy issued an update report and maintained his “Buy rating” and his $10/price target.

Learn More

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed dosing and clinical visits in its Phase 1 study of its proprietary..

finance.yahoo.com

Read Full Article



New American Express Cash Magnet Card Offers 1.5% Unlimited Cash Back & More

Dow 30 component American Express Company (AXP), and its subsidiaries provide customers and businesses globally with charge and credit payment card products and travel-related services. They look to enrich the lives of their customers and build business success.

The American Express Cash Magnet™ Card is the most recent addition to the American Express cash back portfolio. The card offers no annual fees and unlimited 1.5% cash back on purchases, including anything from a cup of coffee to a brand new couch.

With the card comes the option of Pay It Plan It™, the new payment tool that allows Card Members to have flexibility and control over how they will pay for the things they pay. Big purchases can be split up over time with a fixed monthly fee and no interest, while smaller purchases can be payed off as soon as they appear on the card bill. This can all be managed on the Amex Mobile App.

The Cash Magnet Card is also offering a special launch offer through July 18. Card Members have the chance to earn up to $300 cash back. The New Card Members can earn $150 back after spending $1000 in the first 3 months of Card Membership. They can also earn an additional $150 back after spending another $6,500 during the first 12 months of Card Membership.

With all this, the card still features many of the same benefits and services of American Express Card Members such as complimentary ShopRunner members and Amex Offers.

More information on the new Card can be found at americanexpress.com/CashMagnetCard.

Adult Dark Golden Retriever Sits on Multicolored Striped Mat

To learn more about American Express Company (AXP) and to continue to track its progress please visit the Vista Partners American Express Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.




Online Survey Company, SurveyMonkey, Registers for IPO

SurveyMonkey, a U.S. online survey company, announced its confidential registration for an initial public offering (IPO) with the Securities and Exchange Commission. The company has not determined the number of shares offered or the price range or the proposed offerings. Sources reported that the survey company had hired JPMorgan Chase, an investment bank, to help with the preparations for an IPO last month. Alphabet’s CapitalG and Tiger Global Management are investors in the company.

SurveyMonkey is based in San Mateo, CA and has nearly 3 million daily users. The company was formerly run by Dave Goldberg, who is the late husband of Sheryl Sandberg, the Chief Operating Officer of Facebook.

Sliced Avocado on Brown Wooden Board

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

SurveyMonkey confidentially files for IPO

U.S. online survey company SurveyMonkey said it had confidentially registered for an initial public offering with the Securities and Exchange Commission…

www.cnbc.com

Read Full Article



“Hello Volatility” Vista Partners Weekly Market Update 6-16-18

Vista Partners has published “Hello Volatility” Vista Partners Weekly Market Update 6-16-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Comcast Makes Competitive Offer For Fox In Face Off With Disney

The largest provider of cable television in the nation, Comcast, made an offer of $65B in cash to buy 21st Century Fox’s film and TV studios. The bid comes after the already existing Disney bid of $52.4B, all stock. Movies franchises such as Deadpool, X-Men, Planet of the Apes, and Ice Age all belong to Fox. The combination of Comcast and Fox would join Fox to NBC Universal properties and NBC TV channels that include Bravo and SyFy.

Whichever company purchases Fox, will most likely become the controlling owner of Hulu, which is currently 30% owned by each of the three mentioned companies. Hulu seems to be a very important part of the deal.

When broken down, the Comcast offer comes out to $35 per share in cash, which according to Comcast is a 19% premium over the Disney offer. Along with the purchase, Comcast has proposed to pay the $2.5 billion breakup fee Fox had agreed with Disney upon, and the $1.53 billion fee that would’ve been paid to Disney.

Fox has stated that its agreement with Disney still stands but it “will carefully review and consider the Comcast proposal.”

The new deal comes almost a day after the ruling of a federal judge that the telecommunication giant AT&T could purchase Time Warner, just the first of what is predicted to be an onrush of deals brought on by the traditional entertainment powerhouses and service providers looking to outwrestle the increasing competition of Google, Facebook, and Netflix.

With this deal comes a threat to a glorious Marvel reunion. Disney, film right owners to the Avengers, would have the power to unify the comic-book universe with Fox’s rights to X-men and the Fantastic Four.

Disney’s acquisition of Fox represents the epicenter of Disney’s streaming endeavors, and Comcast entering the Fox sweepstakes is a game of high-stakes poker that could change the course of the media and streaming landscape for decades to come, depending on which direction this deal heads.” – Daniel Ives, an analyst at GBH Insights.

Free stock photo of food, sweet, snack, popcorn

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Comcast offers $65 billion to snake Fox from Disney

Comcast wants to sway 21st Century Fox away from Disney with a richer offer…

www.cnet.com

Read Full Article



Merck’s KEYTRUDA Gains Additional Approval From FDA

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research.

Merck recently announced the U.S. Food and Drug Administration’s approval of the company’s anti-PD-1 therapy KEYTRUDA®. The therapy is used to treat patients who have recurrent or metastatic cervical cancer with disease advancement on or after chemotherapy and with tumors that express PD-L1. The indication for the use of this therapy is approved under the FDA’s accelerated approval regulations that are based on both tumor response rate and the durability of response.

KEYTRUDA is now the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer, providing an important new second-line option for certain patients with this disease. This approval also marks the first indication for KEYTRUDA in a gynecologic cancer and reflects our ongoing commitment to bring forward innovative treatment options across a broad range of cancers, including cancers that disproportionately affect women.” -Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories

With KEYTRUDA, some immune-mediated adverse reactions did occur. Those included were as follows: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions, and solid organ transplant rejection.

To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page. 

Free stock photo of landscape, nature, sky, clouds

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

View of City Street

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose..

finance.yahoo.com

Read Full Article



Breast Cancer Innovator Atossa Genetics Adds Former Pfizer & Janssen Pharmacuetica NV Execs To SAB

Seattle based Atossa Genetics Inc. (ATOS) (“Atossa”) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  This week, Atossa appointed two additional pharmaceutical executives to its strategic advisory board (“SAB”) as they named former Pfizer executive, Dr. Makarand (Mak) Jawadekar and Dr. Ajit Shetty, Chairman of the Belgium-based Flemish Institute of Biotechnology and former Janssen Pharmaceutica NV executive. The board is positioned to play a key role in a number of important strategic initiatives in accelerating the clinical development of Atossa’s programs.

Steven Quay, Ph.D., MD, President and CEO of Atossa stated, “We are very excited to have both Dr. Jawadeker and Dr. Shetty join our advisory board.  Each of these lauded industry veterans brings unique sets of talents and experiences to our company. Their insights and direction will be invaluable in developing our strategic initiatives to advance our therapeutics.

Dr. Mak Jawadekar’s professional career at Pfizer, Inc. spanned 28 consecutive years, most recently as a Director, Portfolio Management. During his career at Pfizer, he was responsible for the Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies and has extensive experience in creating and cultivating external partnerships and alliances in this area. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota. Mak was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India in Feb 2011. His years of experience with Pfizer Global R&D includes Solids R&D, Drug Product Formulation/ Dosage Form/Drug Delivery development, Clinical Trials Supply Manufacturing, and Scale-up and Technology Transfer & Research Pharmacy functions. At Pfizer he was also a bench scientist, working on many challenging commercial formulations which became multibillion-dollar products.

Dr. Shetty spent his 40-plus year career at Janssen Pharmaceutica NV in Belgium (a Johnson & Johnson company) in which he drove the expansion of the Janssen Group of Companies through geographical expansion, new product introduction, and significant market share growth. In his prior capacity as President of Janssen Pharmaceutica USA, Dr. Shetty launched Janssen USA into the largest pharmaceutical market. Currently, Dr. Shetty is Chairman of the Belgium-based Flemish Institute of Biotechnology, one of the world’s top-ten research institutions. In 2008, he was awarded the title of Baron by the King of Belgium and in 2004 was elected Manager of the Year by Trends/Flemish Management Association. He is a member of the Board of Directors at Agile Therapeutics, Actinium Pharmaceuticals, and is a member of the Board of Trustees of Carnegie Mellon University.

 

 

 

 

 

 

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the appointment of two additional pharmaceutical executives to its strategic advisory..

finance.yahoo.com

Read Full Article



Bausch + Lomb, ExxonMobil, Westpac Shift Central Workloads to IBM Cloud

International Business Machines Corporation (IBM) provides information technology (IT) products and services worldwide. The Dow 30 component has announced a huge expansion of its cloud abilities. The expansion will aim to unveil 18 new availability zone for the IBM cloud across the areas of North America, Europe, and Asia-Pacific. With the launch, the companies ExxonMobil, Bausch + Lomb and Westpac will be moving their central workloads to the IBM cloud.

The 18 new availability zones will be located in high demand locations such as Germany, UK, Tokyo, Sydney, Washington, D.C., and Dallas, Texas. Even though IBM currently operates in almost 60 locations, it will now possess even more volume and capability in the areas previously listed. Along with the greater location capabilities, clients will also be able to take advantage of multizone Kubernetes clusters across the availability zones through the IBM Cloud Kubernetes Service. The service has simplified how the experience is deployed and managed.

The scope of IBM’s cloud footprint comes at a critical time, with clients looking to achieve better control of their data with data regulations facing tighter regulations.

The world’s biggest companies work with IBM to migrate them to the cloud because we know their technology and unique business needs as they bridge their past with the future. Our continued cloud investment and growing client roster reflect that companies are increasingly seeking hybrid cloud environments that offer cutting-edge tools including AI, analytics, IoT and blockchain to maximize their benefits.

– David Kenny, senior vice president, IBM Watson & Cloud Platform

To learn more about IBM and to track its ongoing progress please visit the Vista Partners IBM Coverage Page.

Person Holding Basketball

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

IBM Unveils Major Expansion of Cloud Capabilities; Industry Leaders ExxonMobil, Bausch + Lomb and Westpac Shift to IBM Cloud

ExxonMobil, the largest publicly traded international oil and gas company, has adopted IBM Cloud as the foundation for their Speedpass+™ mobile app developed by IBM Services. Speedpass+™ is available to motorists at more than 11,000 Exxon and Mobil gas stations across the US…

finance.yahoo.com

Read Full Article



GE Declares Quarterly Dividend Payable July 25, 2018

General Electric Company (GE), headquartered in Fairfield, Connecticut,  is a worldwide infrastructure and financial services company. It combines outstanding engineering with software and analytics to help the world tackle its biggest challenges: energy, health, and transportation.

General Electric Company’s Board of Directors declared a dividend of $0.12 per share on its outstanding common stock on June 8, 2018. The dividend will be payable on Wednesday, July 25, 2018 to those shareholders of record at the close of business on Monday, June 18, 2018.

To track GE’s ongoing progress please visit the Vista Partners GE Company Dedicated Page.

Free stock photo of fashion, man, person, street

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners!

It’s FREE to receive email updates.

Hippos in Water

GE Board of Directors Authorizes Regular Quarterly Dividend

The Board of Directors of GE (GE) today declared a $0.12 per share dividend on the outstanding common stock of the Company. GE encourages investors to visit these websites from time to time, as information is updated and new information is posted…

finance.yahoo.com

Read Full Article